XTNT news

Latest 1 stories · newest Nov 16, 2026

XTNT
Xtant Reports Q3 Results, Announces Board-led Strategic Review

Xtant reported lower Q3 revenue but up 11% biologics performance, prompting the Board to initiate a strategic review of alternatives to maximize value and improve execution.

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same XTNT feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/XTNT/newsSTART FREE